Key Takeaways

• Sun Pharma will acquire Organon for $14.00 per share, valuing the deal at $11.75 billion.
• The merger aims to enhance Sun Pharma’s capabilities in women’s health and biosimilars, elevating its market position globally.
• Approval from Organon stockholders and regulatory bodies is required before the merger can proceed.

Sun Pharma to Acquire Organon in $11.75 Billion Deal

Sun Pharmaceutical Industries Limited has announced its acquisition of Organon & Co. in an all-cash transaction valued at $14.00 per share, approximately $11.75 billion in total enterprise value. This agreement follows a strategic direction for both companies to enhance their market presence and sustainability in the pharmaceutical industry.

Founded as a spinoff from Merck in 2021, Organon specializes in women’s health and general medicines, boasting more than 70 products and a global reach extending to over 140 countries. Its established brand equity and trusted relationships with healthcare professionals and patients position it uniquely in the market. With manufacturing sites spread across the European Union and emerging markets, the company emphasizes accessibility and affordability in healthcare.

The planned acquisition aligns with Sun Pharma’s goals to expand its Innovative Medicines division and strengthens its already significant presence in the Established Brands/Branded Generics sector. Post-acquisition, Sun Pharma anticipates becoming one of the top 25 pharmaceutical companies globally, with combined revenues projected to reach $12.4 billion and significant revenue generation through its established brands, including a transition into the biosimilars market, rounding out its portfolio as a leading player in women’s health.

Upon finalization of the deal, Sun Pharma will increase its market footprint to include 150 countries and 18 major markets where it expects to generate at least $100 million in revenue each. This strategic move is expected to double cash flow and EBITDA, enhancing the company’s financial strength while allowing for efficient debt management.

Both companies’ Boards of Directors have approved the transaction, but it is subject to customary closing conditions including regulatory approvals and approval from Organon stockholders. Key executives have expressed optimism about merging the two organizations, highlighting the potential for significant synergies, enhanced capacity for new product launches, and a robust future growth platform.

Dilip Shanghvi, Executive Chairman of Sun Pharma, remarked on the opportunity this acquisition presents for sustainable long-term growth, emphasizing the complementary nature of the two firms. Kirti Ganorkar, Managing Director at Sun Pharma, noted that leveraging Organon’s talent pool and capabilities will drive business continuity and value creation in the coming years.

Carrie Cox, Executive Chair of Organon, affirmed that this deal offers immediate value to its stockholders while supporting the company’s mission globally.

The transaction’s closing is anticipated in early 2027, pending the fulfillment of all necessary approvals. This acquisition positions Sun Pharma ambitiously for future growth while fostering innovation in healthcare solutions, particularly focusing on women’s health and overall pharmaceutical advancements.

The content above is a summary. For more details, see the source article.